Johnson & Johnson or Exelixis, Inc.: Who Invests More in Innovation?

Comparing R&D Investments: Johnson & Johnson vs. Exelixis, Inc.

__timestamp	Exelixis, Inc.	Johnson & Johnson
Wednesday, January 1, 2014	189101000	8494000000
Thursday, January 1, 2015	96351000	9046000000
Friday, January 1, 2016	95967000	9095000000
Sunday, January 1, 2017	112171000	10554000000
Monday, January 1, 2018	182257000	10775000000
Tuesday, January 1, 2019	336964000	11355000000
Wednesday, January 1, 2020	547851000	12340000000
Friday, January 1, 2021	693716000	14277000000
Saturday, January 1, 2022	891813000	14135000000
Sunday, January 1, 2023	1044071000	15048000000
Monday, January 1, 2024	910408000	17232000000

Infusing magic into the data realm

Innovation Investment: A Tale of Two Companies

In the ever-evolving landscape of pharmaceuticals and biotechnology, innovation is the lifeblood of progress. Johnson & Johnson and Exelixis, Inc. are two giants in this field, each with a distinct approach to research and development (R&D) investment. Over the past decade, Johnson & Johnson has consistently outpaced Exelixis, Inc. in R&D spending, with an average annual investment of approximately $11.5 billion, compared to Exelixis, Inc.'s $419 million. This represents a staggering 2,645% higher investment by Johnson & Johnson.

From 2014 to 2023, Johnson & Johnson's R&D expenses grew by 77%, peaking at $15 billion in 2023. Meanwhile, Exelixis, Inc. saw a remarkable 448% increase, reaching $1 billion in the same year. These figures highlight the contrasting scales and growth trajectories of these companies, underscoring the diverse strategies in the pursuit of innovation.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025